Multiple Sclerosis. Everything you need to know

Intramuscular Interferons Beta-1a

The next drug to hit the MS market after Betaseron was Avonex, registered by Biogen in 1996. Its active ingredient was interferon beta-1a. Instead of growing it in E. coli bacteria, Biogen cultivated it using mammalian cells—specifically, "Chinese hamster ovary cells." This molecular structure was much closer to natural human interferon-beta. Biogen cleverly marketed this as a "natural form," using it to explain why Avonex had milder side effects compared to Betaseron.

There was also a fundamental shift in how the drug was taken: Avonex was injected just once a week, not every other day. Manufacturing it in hamster cells made the molecule far more stable in the body. Furthermore, since subcutaneous injections of Betaseron too frequently caused painful skin reactions, Biogen offered intramuscular injections. To top it all off, they drastically slashed the weekly dosage—from 250 micrograms down to 30 micrograms.

Do you see the pattern? By the time the second interferon arrived, the industry’s focus had already shifted away from maximizing medical efficacy. Instead, they were trying to make the grueling injection routine slightly less miserable for the patient. In any other industry, this is the exact moment you say "the customer service department has arrived."

You have to hand it to Biogen: their entire regulatory launch strategy for Avonex was a masterpiece of marketing and pharmaceutical positioning. They studied Betaseron’s success story inside out, connected the dots, and drew the right financial conclusions. They listened to what patients hated about the first miracle drug and turned those medical complaints into a corporate gold mine.

First of all, they realized that patients desperately wanted to avoid stabbing themselves every other day while enduring a never-ending cycle of fevers. Biogen’s fix was elegant: a vastly reduced dose of interferon injected only once a week. In the eyes of both doctors and patients, this single tweak made the drug look like a quantum leap forward. Once a week is incomparably more convenient than every other day, isn't it? You can easily plan a weekend trip without dragging a cooling kit along or trying to remember when you last did an injection. You only have to endure the flu-like misery once a week, and those symptoms turned out to be noticeably milder anyway. Whichever way you looked, it was a massive win for user experience.

Secondly, Biogen’s strategists realized that their clients (at this stage, calling them "patients" feels a bit naive) weren't idiots. Some scoured the medical journals themselves, while others tracked the scientific pushback against Betaseron. They weren't just demanding fewer relapses anymore; they wanted proof that a drug could actually slow down long-term disability progression. Biogen delivered exactly what the market ordered. Their clinical trials came back with a spectacular claim: the risk of "confirmed disability progression" for patients on Avonex was slashed by 37% compared to the placebo group.

The third season of the American Crime Story focuses on a scandal you likely haven’t forgotten: Bill Clinton and Monica Lewinsky. The season spans 10 full hour-long episodes, and if you think that’s an excessive runtime to cover a straightforward historical event, you underestimate the legal battle of an impeachment trial. I won’t recap the whole drama, but there is one pivotal moment worth highlighting. When Clinton was cornered under oath and asked if he had engaged in sexual relations with Monica Lewinsky, his lawyers said: "Define sexual relations." The prosecutor read the strict, technical definition from the official vocabulary log, and Clinton answered with a completely clear conscience that, under those exact definitions, he had not. If required, he could have passed a polygraph on the spot. The impeachment collapsed, and Clinton remained in the Oval Office until the end of his term.

Why bring this up? When multiple sclerosis patients demanded that interferons slow down their disability, Biogen replied, "Absolutely. But first, let’s define what qualifies as a slowdown." Biogen defined "disability progression" as an increase of 1.0 full point on the EDSS scale, which then had to be verified by a repeat audit six months later. They termed this metric SDP—Sustained Disability Progression. Soon, the industry would rebrand it as CDP, Confirmed Disability Progression, and it remains a core endpoint in DMT trials to this day. But here is the critical catch: if after six months the patient's walking or coordination naturally bounced back to baseline and the deterioration failed to confirm, the "odometer" was entirely wiped clean—the progression was logged as unconfirmed. Furthermore, the calculation completely ignored the patient's starting line, erasing the massive functional difference between shifting from 1.0 to 2.0 versus dropping from 5.0 to 6.0. The non-linear nature of the EDSS manufactures a wall of statistical "noise" spanning dozens of percentage points. Under unblinded conditions, the loose handling of scores below 3.5 leaves researchers massive room to steer the metrics. Once the stage was set for these statistical miracles, all Biogen had to do was navigate the blinding problem.

As their corporate attorneys predicted, the blinding issue resolved itself because the FDA had trapped itself with its 1993 Betaseron ruling. By approving the first interferon despite an entirely compromised trial design, the agency had locked in a legal precedent. Tightening the scientific screws on the very next drug would be an implicit admission that their initial standard was dangerously low. Bureaucratic regulators almost never do this—partly out of sheer institutional inertia, and partly out of fear of nuking public trust in their own past decisions. The FDA officials chose not to rock the boat, likely comforting themselves with thoughts like: "Well, the scientists engineered it, so it must do something useful."

Let’s look at a few numbers to put the scale of this market into perspective:

In its 2007 financial report, Biogen stated that the number of patients on Avonex crossed 135,000, translating to roughly 7 million injections a year.

At launch, a single injection cost about $250. By the early 2000s, that bounced to $400–$500. By the 2010s, it hit $600 per shot.

Over 25 years, anywhere from 600,000 to 700,000 patients cycled through Avonex therapy.

Cumulatively, patients stuck themselves with Avonex between 50 and 70 million times.

Total global sales for Avonex look back on a mountain of roughly $40 billion.

The regulatory compromise the FDA signed under public duress in 1993 did not happen in a vacuum. It forged a precedent that permanently rewrote the rules of the game: clinical trials for DMTs were effectively excused from maintaining strict double-blinding, rigorous efficacy filters, or clinically meaningful endpoints. A drug whose utility was proven purely at the level of loose definitions and statistical assumptions transformed into a multi-billion-dollar corporate juggernaut—and laid down the new baseline framework for how the entire industry would operate for decades. Patients desperately wanted a weapon against multiple sclerosis, and the market gave them exactly what they asked for.

Let's look under the hood of the Avonex trials. The study was exceptionally small, tracking just 301 people: 158 patients injected Avonex, while 143 were given a neutral solution as a placebo. Defining what actually constituted a "relapse" was left entirely to the discretion of the investigators. Because a new interferon molecule was practically pre-ordained for commercial success under the existing rules, Biogen had zero financial incentive to fund a massive, multi-center trial. Nobody wanted to dig into the Pandora's box that Betaseron had opened. In May 1996, Avonex sailed through FDA approval, hit US pharmacies by summer, and locked in the precedent: DMTs could legally claim efficacy without bulletproof double-blinding.

But what about the fact that Avonex actually showed lower real-world efficacy because of its slashed dosage and weekly schedule? The drop in performance was real: the trials proved Avonex lowered relapses by only 18%, compared to Betaseron’s 31%. To spin the launch of a less effective drug to the public, the marketing departments simply deployed a single, devastating counter-punch: "Betaseron had zero proven impact on long-term disability, but Avonex slows it down by 37%." I can easily visualize the Biogen executives trying to smother their laughter in corporate boardrooms. Meanwhile, the team at Schering/Bayer must have been utterly sick to their stomachs when they realized how badly they had botched their own data mapping by failing to lock down a disability endpoint. That single mistake evaporated billions of dollars.

The most incredible part of this narrative? Nobody in the medical community seemed bothered by the logical contradiction: a heavy dose of Betaseron (250 mcg every other day) reduces relapses by 31% but fails to alter disability, while a tiny dose of Avonex (30 mcg once a week) reduces relapses by just 18% but magically slows disability by 37%. Let's look at the weekly math: an Avonex patient takes 30 mcg a week, while a Betaseron patient takes 875 mcg a week—a nearly 30-fold difference in active compound. It brings to mind the old idiom about trying to pass off rain as a divine blessing.

I couldn't find exact global registries for the total MS population in 1996, but the corporate press releases from Biogen and Teva during that era continue to quote the exact same static estimate from 1993: 250,000 patients in the US. It was right around this window that MRI scanners began their rapid, systemic rollout across municipal hospitals. By 2001, the first version of the McDonald criteria was officially adopted, anchoring the MRI as the absolute center of MS diagnostics. Almost instantly, the official patient counts in the United States began a steep, relentless climb.

Subcutaneous Interferons Beta-1a

Patients demanded a slowdown in their disability progression, and now interferons were more than ready to give it to them. In reality, the only limits on these numbers were set by common sense. Pushing a trial design to show a 50% disability slowdown wouldn’t have been that difficult given the elastic nature of the EDSS scale, but doing so would have drawn a dangerous amount of scientific scrutiny to the drugs. By the way, I suspect the relatively high figure of 37% chosen by Biogen was a calculated tactical move. If the manufacturers of Betaseron had been a bit bolder and "proven" a 60% relapse reduction, everyone else in the market would have had far more breathing room to manipulate their own data.

The next titan to step onto the interferon battlefield was Rebif. The molecule was engineered by the Swiss biotech firm Serono in 1998, and it almost instantly sailed through European regulatory approval. However, its launch in the United States got bogged down for years—not because of the FDA, but due to vicious patent litigation between the pharmaceutical giants. Serono wanted to patent their specific manufacturing tech and proprietary formulation of interferon-beta-1a, which was tricky considering Biogen’s near-identical Avonex was already selling out worldwide. Still, Rebif brought one key operational upgrade to the table: it was injected subcutaneously (under the skin) rather than deep into the muscle.

Serono’s legal and marketing teams took a far more aggressive track than their rivals. They set out not just to capture a slice of the market, but to lock down exclusive rights to the underlying tech and freeze out future competitors. They claimed that their signature bio-reactor setup yielded a completely peerless molecule—an interferon so uniquely potent that contrasting it with existing brands was structurally incorrect. Furthermore, they asserted that the scientists at Biogen were dead wrong or had actively misled the medical community: to actually change the course of multiple sclerosis, you had to inject interferon beta-1a three times a week, and it had to go under the skin. Never mind that the molecule was supposed to be highly stable in the human body. Sure, the patient would have to endure a non-stop, three-fold increase in fevers and skin reactions, but we are talking about modifying an incurable disease here! This wasn't the place for soft compromises or comfort.

The US chewing gum market in the 1970s and 1980s was saturated to absolute capacity. Five massive conglomerates led by Wrigley had hit a wall where scaling sales volume was physically impossible: gum was already sold at every cash register, and everyone who wanted to chew was already chewing. Wrigley’s marketing strategists solved this market saturation with a stroke of genius: they decided to force existing consumers to double their consumption. They launched a wave of hypnotic TV commercials showing people experiencing pure bliss by tossing two pieces of gum into their mouths at once. The ad copy hammered home the message: Double your pleasure, double your fun, double your mint. I think you know the results of that campaign just as well as I do.

Let's look at the financial math behind Rebif:

The drug rolled off the line in two distinct strengths—22 mcg and 44 mcg. Bizarrely, both tracks required three injections a week. The 22 mcg was the baseline, but patients whose bodies tolerated the side effects were urged to double the dose to unlock "maximum efficacy." How this double-up shifted the biological baseline was never clearly mapped out, but a single 22 mcg shot in the 2010s cost about $300, while the 44 mcg version retailed for $400. It looks a lot like the pricing strategy for a small versus a large cappuccino, doesn't it?

At launch, a year of Rebif therapy was priced roughly 1.5 times higher than both Betaseron and Avonex.

The clinical trials claimed Rebif cut relapses by 29–32% and slowed disability by 23–31%. Remember, Avonex claimed an 18% relapse drop and a 37% disability slowdown. Don't ask me how this mathematical contradiction is biologically possible—nobody knows.

By 2003, Rebif sales shattered the $800 million mark, accounting for a massive 44.1% of Serono’s total corporate revenue.

In 2013, global Rebif sales soared to roughly $2.5 billion, locking it in as the third best-selling multiple sclerosis drug on Earth.

Cumulatively, Rebif has drained global healthcare budgets to the tune of $24 billion.

Do you think the market hit equilibrium there? Not even close. This entire pharmaceutical crossfire unfolded right at the dawn of mass MS diagnostics via MRI. Rebif unlocked its US registration in 2002, and over the subsequent three years, the estimated number of diagnosed patients in the United States exploded from 250,000 to 400,000. This spike was driven entirely by the systemic rollout of tomographs and the arrival of the 2001 McDonald criteria. Pharmaceutical companies launched a highly aggressive medical campaign branded as the "Window of Opportunity." Sales reps bombarded neurologists with the message that every single day a patient spends without therapy results in the irreversible burning away of their brain tissue. Doctors were urged to abandon years of clinical observation and slap on a diagnosis at the absolute first hint of trouble. Happiness for everyone, and let no one leave empty-handed!

Pegylated Interferons Beta-1a

Pegylation is a biochemical process where an interferon molecule is structurally bound to a chain of polyethylene glycol (PEG). This modification cloaks the interferon, making it incredibly stable and resilient against the body’s clearing enzymes. It drastically extends the drug's half-life, which, in plain terms, allows the patient to slash the frequency of their injections. When Rebif's trial data established a new benchmark for corporate performance, everyone else in the market who wanted to secure a piece of the relapsing-remitting MS gold mine had to cook up something radically fresh. Playing around with minor tweaks to dosages, injection schedules, relapse rates, and EDSS charts could only carry a brand so far—eventually, even the FDA’s patience would bottom out.

By the late 1990s, Rebif had cannibalized a massive chunk of Avonex’s market share, and the board of directors at Biogen was feeling the heat. Things looked exceptionally bleak in Europe, where Rebif had bypassed legal blockades and registered instantly—the US market had been insulated until 2002 solely by Biogen's scorched-earth courtroom tactics. Rebif's trials proved it was more effective, which made perfect logical sense given the three-times-a-week injection schedule, and Avonex’s long-term market position looked dead in the water. But the executives at Biogen understood the mechanics of the pharmaceutical industry inside out. They launched a long-term counter-offensive years before the trap snapped shut.

The engineering of an interferon with an extended half-life kicked off around 2003–2004, serving as a direct corporate answer to Serono's offensive. There was zero running room left within the boundaries of existing interferon parameters, so to keep the cash flowing, they had to introduce a brand-new variable to the board. They needed the illusion of an absolute breakthrough—a scientific miracle. They needed a product that doctors could pitch to scared patients as a revolutionary new weapon. It was an incredibly complex marketing puzzle, but when you are chasing billions of dollars, nothing is impossible: in the summer of 2014, a drug called Plegridy hit the shelves simultaneously in Europe and the United States.

The trial design for Plegridy mirrored the industry's gold standards: a basic saline solution as a placebo, completely unblinded conditions driven by violent side effects, and cleanly positive yet utterly unremarkable medical results. However, the study—code-named ADVANCE—featured one fascinating structural twist. During the first phase, they contrasted Plegridy against the placebo, but in the second phase, they compared Plegridy injected once every 2 weeks against Plegridy injected once every 4 weeks. Biogen clearly wanted to lock down and monopolize the optimal injection schedule for long-acting interferons. Crucially, they never ran a direct comparison between a once-a-week and a once-every-two-weeks track. If a patient wanted a weekly shot, Biogen already had a product for that: Avonex.

Let's look at the facts behind Plegridy:

Injected once every 2 weeks, Plegridy lowered the annual relapse rate by 36%.

Injected once every 4 weeks, it reduced relapses by 28%. By publishing data on less frequent dosing, Biogen didn't just give patients an illusion of choice; they mathematically "proved" to them that taking the shot kept the disease down, while backing off increased the risk of flare-ups.

Plegridy cut the risk of confirmed disability progression by 38%.

A massive 71% of patients on the bi-weekly Plegridy track went the entire year of the study without a single registered relapse.

By the way, the fact that Plegridy could be taken so infrequently wasn't just a miracle of pegylation—it was also fueled by a massive increase in the active compound. The titration schedule makes this obvious. The first shot is 63 mcg in an orange syringe; the second is 94 mcg in a blue one; and then you transition to a standard 125 mcg dose in gray syringes. This means the maintenance dose is more than four times larger than Avonex—despite the pegylated shield and the extended half-life. Naturally, this question was repeatedly raised at medical congresses. Biogen’s official corporate answer was that a massive volume of the active compound was mandatory to stretch the therapeutic plateau for a flawless 14 days, matching the efficacy of high-frequency shots. Remarkably, cranking up the chemical volume had almost zero impact on the severity of the flu-like side effects.

This brings us right back to MS diagnostics via MRI. Throughout the 2000s and 2010s, the official multiple sclerosis patient counts in the United States were swelling like rising dough—epidemiological surveys show the numbers jumping from 400,000 in 2003 to a massive 900,000 by 2019. Under the influence of loose diagnostic criteria and ubiquitous MRI scanners, the average "profile" of an MS patient shifted completely. The newer interferons looked incomparably more effective on paper—not because the molecules had undergone a biological evolution, but because the trial pools were increasingly packed with early-stage, asymptomatic, and highly ambiguous cases. In 1998, during the Rebif trials, the placebo group averaged 1.28 relapses a year. By 2014, in the Plegridy trials, the placebo group’s relapse rate plummeted to a measly 0.40. The old-school interferons would have loved to test their steel against this fresh, mild pool of patients, but unfortunately, that's not how the market works.